Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + PD-1 Monoclonal Antibody in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06437522Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in head and neck squamous cell carcinoma (HNSCC), solid tumor, sponsored by Biokin Pharmaceutical. Started Jun 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)solid tumor
Beyond the preview
Go deeper on NCT06437522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437522.